MTACU has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MTACU has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. MedTech Acquisition's Operating Income for the three months ended in Jun. 2023 was $-1.43 Mil. MedTech Acquisition's Interest Expense for the three months ended in Jun. 2023 was $0.00 Mil. MedTech Acquisition has no debt. The higher the ratio, the stronger the company's financial strength is.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for MedTech Acquisition's Interest Coverage or its related term are showing as below:
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for MedTech Acquisition's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MedTech Acquisition Annual Data | |||||||
Trend | Dec20 | Dec21 | Dec22 | ||||
Interest Coverage | No Debt | N/A | N/A |
MedTech Acquisition Quarterly Data | ||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Interest Coverage | Get a 7-Day Free Trial | N/A | N/A | N/A | No Debt | No Debt |
For the Shell Companies subindustry, MedTech Acquisition's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Diversified Financial Services industry and Financial Services sector, MedTech Acquisition's Interest Coverage distribution charts can be found below:
* The bar in red indicates where MedTech Acquisition's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
If Interest Expense is negative and Operating Income is positive, then
Interest Coverage | = | -1 | * | Operating Income | / | Interest Expense |
Else if Interest Expense is negative and Operating Income is negative, then
The company did not have earnings to cover the interest expense. |
Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then
The company had no debt (1). |
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
MedTech Acquisition's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as
Here, for the fiscal year that ended in Dec. 2022, MedTech Acquisition's Interest Expense was $0.00 Mil. Its Operating Income was $-2.75 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.34 Mil.
GuruFocus does not calculate MedTech Acquisition's interest coverage with the available data. |
MedTech Acquisition's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as
Here, for the three months ended in Jun. 2023, MedTech Acquisition's Interest Expense was $0.00 Mil. Its Operating Income was $-1.43 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
MedTech Acquisition had no debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's Financial Strength is.
MedTech Acquisition (NAS:MTACU) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thank you for viewing the detailed overview of MedTech Acquisition's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Magnetar Financial Llc | 10 percent owner | 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201 |
Magnetar Capital Partners Lp | 10 percent owner | 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201 |
Supernova Management Llc | 10 percent owner | 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201 |
David J. Snyderman | 10 percent owner | C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201 |
David L Treadwell | director | 222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102 |
Manuel Aguero | director | 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022 |
Thierry B. Thaure | director | 3957 POINT EDEN WAY, HAYWARD CA 94545 |
David J Matlin | director, 10 percent owner, officer: Chief Financial Officer | |
Karim Karti | director | C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103 |
Christopher C Dewey | director, 10 percent owner, officer: Chief Executive Officer | 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271 |
Robert H. Weiss | officer: Chief Admin Officer and Sec. | 585 WEED STREET, NEW CANAAN CT 06840 |
Maurice R Ferre | director | C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317 |
Ivan Delevic | director | C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317 |
Medtech Acquisition Sponsor Llc | 10 percent owner | 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105 |
Martin William Roche | director | 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022 |
From GuruFocus
By PRNewswire PRNewswire • 09-09-2021
By GuruFocus Research • 07-28-2023
By Marketwired Marketwired • 02-06-2021
By GuruFocusNews GuruFocusNews • 03-10-2022
By Business Wire Business Wire • 02-21-2023
By GuruFocus Research • 08-15-2023
By PRNewswire PRNewswire • 08-19-2021
By Marketwired Marketwired • 12-23-2020
By Business Wire Business Wire • 06-12-2023
By PRNewswire PRNewswire • 08-13-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.